Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866017 | 0.84 | PDE9A (0.59) | PDE9APDE1C | |
| SCHEMBL4512357 | 0.82 | KMT2A (0.53) | — | |
| SCHEMBL4590772 | 0.82 | PDE9A (0.53) | PDE9APDE1C | |
| SCHEMBL4510882 | 0.82 | PDE10A (0.44) | PDE9APDE1C | |
| SCHEMBL13865963 | 0.81 | PDE9A (0.50) | PDE9APDE1C | |
| SCHEMBL13865962 | 0.81 | PDE9A (0.50) | PDE9APDE1C | |
| SCHEMBL4501728 | 0.81 | PDE9A (0.54) | PDE9APDE1C | |
| SCHEMBL13865776 | 0.79 | PDE9A (0.58) | PDE9APDE1C | |
| SCHEMBL13865992 | 0.79 | PDE9A (0.53) | PDE9APDE1C | |
| SCHEMBL13866015 | 0.78 | PDE9A (0.64) | PDE9APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE9A 40/4885PDE1C 14/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | PDE9A 29/4885PDE1C 15/4885 |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | PDE9A 13/4885PDE1C 190/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE9A 40/4885PDE1C 14/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | PDE9A 34/4885PDE1C 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.